Makind Pharma Limited v. The Registrar Of Trade Marks

In the crowded world of consumer brands, some of the most powerful trademarks are the ones that sound almost too ordinary to protect. Phrases we use every day — like "Don't Worry" — sit at the exact intersection of language and law, where registrars often slam the door shut on the grounds of descriptiveness or lack of distinctiveness. But what happens when a company has already built a recognizable identity around such a phrase across multiple product categories? That was the central question in a recent Delhi High Court showdown between Mankind Pharma Limited and the Registrar of Trade Marks, and the answer reshaped how brand portfolios can be leveraged to push through stubborn objections.

Mankind Pharma Limited, a well-known player in the pharmaceutical and consumer goods space, sought to register the trademark "DON'T WORRY" in Class 3, a category that typically covers cosmetics, cleaning preparations, and similar goods. The Registrar of Trade Marks refused the application, leaning on the conventional view that the words "Don't" and "Worry" are everyday expressions lacking the inherent distinctiveness required for registration as a standalone mark. This refusal set the stage for Mankind Pharma to challenge the decision before the Delhi High Court, armed with a critical piece of context: the company already held existing registrations of the "DON'T WORRY" mark across various other classes, including the registered trademark "MANKIND'S DON'T WORRY."

The legal friction in this case centered on a single but powerful question — should a mark that has already been registered and used by the same applicant across multiple classes be refused in a new class purely on the ground that its individual words are common or descriptive? Mankind Pharma argued that the Registrar's refusal was unwarranted given its established portfolio of "DON'T WORRY" registrations. The company contended that its consistent and repeated use of the phrase across categories had built a recognizable brand identity that deserved protection. On the other side, the Registrar stood by the traditional position that "Don't" and "Worry" are ordinary English words, incapable on their own of distinguishing the source of goods in Class 3. The core tension was between rigid distinctiveness rules and the practical reality of a brand that had already cleared those hurdles elsewhere.

The Delhi High Court came down firmly in Mankind Pharma's favor, allowing the appeal and setting aside the Registrar's refusal. The court held that, given the Appellant's existing registrations of the mark across various classes, a refusal based solely on lack of distinctiveness was unwarranted. The application was directed to proceed for advertisement before acceptance, but with two important conditions attached. First, the mark had to be associated with the already registered trademark "MANKIND'S DON'T WORRY," tying the new registration to the company's broader brand identity. Second, and critically, no exclusive rights were to be granted in the words "DON'T" or "WORRY" taken alone — meaning Mankind Pharma could protect the phrase as a composite mark, but could not monopolize the individual common words within it.

For founders and IP professionals, this case delivers a clear strategic lesson: a well-maintained, multi-class trademark portfolio is not just a defensive shield — it is an offensive weapon. When a registrar objects to a new application on grounds of descriptiveness or lack of distinctiveness, evidence of existing registrations and consistent use of the same mark across other classes can tip the scales in your favor. However, the court's conditions also carry a warning. Registering a phrase built from common words comes with strings attached — your protection may be limited to the composite mark, and you may be required to associate it with your broader brand identity. Smart brand builders should think of every trademark filing not in isolation, but as part of a connected portfolio that reinforces distinctiveness over time.